Financial Ratios Myriad Genetics, Inc.
Equities
MYGN
US62855J1043
Medical Equipment, Supplies & Distribution
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.365 USD | +0.48% |
|
-3.41% | -46.24% |
| Nov. 26 | Sector Update: Health Care Stocks Edge Higher Premarket Wednesday | MT |
| Nov. 25 | Myriad Genetics Collaborates With Clairity, MagView to Roll Out AI Platform for Breast Cancer Risk Assessment | MT |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -5.68 | -5.78 | -6.14 | -7.4 | -5.06 | |||||
Return on Total Capital | -6.65 | -7.1 | -7.4 | -8.83 | -6.19 | |||||
Return On Equity % | -19.89 | -2.94 | -12.08 | -31.55 | -17.15 | |||||
Return on Common Equity | -19.88 | -2.94 | -12.08 | -31.55 | -17.15 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 69.51 | 71.39 | 70.22 | 68.64 | 69.89 | |||||
SG&A Margin | 85.69 | 77.87 | 75.87 | 75.31 | 66.86 | |||||
EBITDA Margin % | -16.18 | -9.25 | -10.47 | -10.98 | -3.2 | |||||
EBITA Margin % | -17.85 | -11 | -12.18 | -12.76 | -5.48 | |||||
EBIT Margin % | -28.12 | -18.35 | -18.23 | -18.44 | -10.51 | |||||
Income From Continuing Operations Margin % | -17.71 | -3.94 | -16.51 | -34.96 | -15.2 | |||||
Net Income Margin % | -17.71 | -3.94 | -16.51 | -34.96 | -15.2 | |||||
Net Avail. For Common Margin % | -17.71 | -3.94 | -16.51 | -34.96 | -15.2 | |||||
Normalized Net Income Margin | -18.89 | -12.05 | -11.4 | -11.8 | -6.57 | |||||
Levered Free Cash Flow Margin | 17.15 | 21.79 | -17.06 | -8.16 | 1.58 | |||||
Unlevered Free Cash Flow Margin | 18.2 | 22.39 | -16.76 | -7.91 | 1.79 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.43 | 0.5 | 0.54 | 0.64 | 0.77 | |||||
Fixed Assets Turnover | 7.97 | 6.12 | 4.34 | 4.09 | 4.75 | |||||
Receivables Turnover (Average Receivables) | 6.32 | 7.64 | 7.03 | 6.98 | 7.11 | |||||
Inventory Turnover (Average Inventory) | 6.15 | 9.32 | 11.41 | 11.22 | 10.19 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.67 | 2.37 | 2 | 2.01 | 1.82 | |||||
Quick Ratio | 1.66 | 2.11 | 1.58 | 1.64 | 1.36 | |||||
Operating Cash Flow to Current Liabilities | -1.01 | 0.09 | -0.77 | -0.71 | -0.05 | |||||
Days Sales Outstanding (Average Receivables) | 57.89 | 47.78 | 51.89 | 52.31 | 51.45 | |||||
Days Outstanding Inventory (Average Inventory) | 59.49 | 39.16 | 31.98 | 32.53 | 35.92 | |||||
Average Days Payable Outstanding | 54.76 | 49.21 | 51.54 | 41.85 | 41.26 | |||||
Cash Conversion Cycle (Average Days) | 62.62 | 37.73 | 32.34 | 42.99 | 46.11 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 32.8 | 9.54 | 16.37 | 19.42 | 20.01 | |||||
Total Debt / Total Capital | 24.7 | 8.71 | 14.07 | 16.26 | 16.67 | |||||
LT Debt/Equity | 31.26 | 8.19 | 14.78 | 17.35 | 18.19 | |||||
Long-Term Debt / Total Capital | 23.54 | 7.48 | 12.7 | 14.53 | 15.15 | |||||
Total Liabilities / Total Assets | 37.91 | 26.72 | 26.1 | 31.69 | 31.77 | |||||
EBIT / Interest Expense | -14.53 | -19.2 | -38.66 | -47.9 | -31.43 | |||||
EBITDA / Interest Expense | -8.36 | -6.55 | -15.72 | -19.59 | -2.07 | |||||
(EBITDA - Capex) / Interest Expense | -9.72 | -9.27 | -29.88 | -41.38 | -8.86 | |||||
Total Debt / EBITDA | -2.98 | -2.14 | -2.88 | -2.68 | -24.19 | |||||
Net Debt / EBITDA | -1.21 | 7.09 | 0.49 | -0.2 | -6.53 | |||||
Total Debt / (EBITDA - Capex) | -2.56 | -1.51 | -1.52 | -1.27 | -5.66 | |||||
Net Debt / (EBITDA - Capex) | -1.04 | 5.01 | 0.26 | -0.09 | -1.53 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -24.97 | 23.99 | -1.77 | 11.03 | 11.21 | |||||
Gross Profit, 1 Yr. Growth % | -30.4 | 30.15 | -3.37 | 8.52 | 13.23 | |||||
EBITDA, 1 Yr. Growth % | -161.27 | -48.22 | 11.11 | -0.36 | -67.59 | |||||
EBITA, 1 Yr. Growth % | -183.11 | -43.07 | 8.68 | 1.59 | -52.24 | |||||
EBIT, 1 Yr. Growth % | -556.95 | -34.96 | -2.37 | 2.36 | -36.65 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -4.64K | -87.85 | 311.76 | 135.09 | -51.65 | |||||
Net Income, 1 Yr. Growth % | -4.44K | -87.84 | 311.76 | 135.09 | -51.65 | |||||
Normalized Net Income, 1 Yr. Growth % | -738.34 | -29.35 | -7.13 | 4.79 | -38.12 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -4.58K | -88.31 | 297.14 | 128.78 | -55.66 | |||||
Accounts Receivable, 1 Yr. Growth % | -49.14 | 2.01 | 11.28 | 12.5 | 6.04 | |||||
Inventory, 1 Yr. Growth % | -7.32 | -43.54 | 31.37 | 9.45 | 25 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 79.76 | 24.8 | 49.48 | -3.58 | -4.54 | |||||
Total Assets, 1 Yr. Growth % | -10.12 | -6.91 | -9.24 | -4.35 | -10.37 | |||||
Tangible Book Value, 1 Yr. Growth % | 13.08 | -1.28K | -33.23 | -33.22 | 5.15 | |||||
Common Equity, 1 Yr. Growth % | -15.68 | 9.85 | -8.47 | -11.58 | -10.48 | |||||
Cash From Operations, 1 Yr. Growth % | -27.48 | -167.66 | -671.51 | 4.33 | -92.16 | |||||
Capital Expenditures, 1 Yr. Growth % | 18.6 | 36.36 | 151.67 | 39.51 | -69.94 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 83.3 | - | -177.41 | -50.15 | -121.57 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 72.89 | - | -174.03 | -50.82 | -125.16 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | -7.34 | - | 10.36 | 4.43 | 11.12 | |||||
Gross Profit, 2 Yr. CAGR % | -10.63 | - | 12.15 | 2.41 | 10.85 | |||||
EBITDA, 2 Yr. CAGR % | -26.13 | - | -24.15 | 13.76 | -38.56 | |||||
EBITA, 2 Yr. CAGR % | -13.22 | - | -21.34 | 12.45 | -25.46 | |||||
EBIT, 2 Yr. CAGR % | 49.02 | - | -20.31 | 4.7 | -15.66 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 22.46 | - | -29.26 | 211.13 | 6.61 | |||||
Net Income, 2 Yr. CAGR % | 22.34 | - | -29.24 | 211.13 | 6.61 | |||||
Normalized Net Income, 2 Yr. CAGR % | 54.76 | - | -19 | 3.32 | -15.66 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 20.58 | - | -31.87 | 201.43 | 0.72 | |||||
Accounts Receivable, 2 Yr. CAGR % | -17.27 | - | 6.55 | 11.89 | 9.22 | |||||
Inventory, 2 Yr. CAGR % | -7.89 | - | -13.88 | 19.91 | 16.97 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 54.41 | - | 36.58 | 20.06 | -4.06 | |||||
Total Assets, 2 Yr. CAGR % | 9.32 | - | -8.08 | -6.83 | -7.41 | |||||
Tangible Book Value, 2 Yr. CAGR % | -72.35 | - | 180.34 | -33.23 | -16.2 | |||||
Common Equity, 2 Yr. CAGR % | -2.51 | - | 0.27 | -10.04 | -11.03 | |||||
Cash From Operations, 2 Yr. CAGR % | -27.63 | - | 98.79 | 144.18 | -71.39 | |||||
Capital Expenditures, 2 Yr. CAGR % | 10.19 | - | 85.25 | 87.38 | -35.24 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 595.69 | - | - | -35.9 | -66.16 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 2K | - | - | -37.7 | -63.68 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | -4.3 | - | - | 10.58 | 6.64 | |||||
Gross Profit, 3 Yr. CAGR % | -6.72 | - | - | 10.92 | 5.89 | |||||
EBITDA, 3 Yr. CAGR % | -11.79 | - | - | -12.49 | -25.15 | |||||
EBITA, 3 Yr. CAGR % | -1.19 | - | - | -10.38 | -15.47 | |||||
EBIT, 3 Yr. CAGR % | 46.13 | - | - | -10.66 | -11.44 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 126.4 | - | - | 5.57 | 67.27 | |||||
Net Income, 3 Yr. CAGR % | 125.49 | - | - | 5.58 | 67.27 | |||||
Normalized Net Income, 3 Yr. CAGR % | 52.09 | - | - | -8.97 | -12.91 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 120.77 | - | - | 2.02 | 59.12 | |||||
Accounts Receivable, 3 Yr. CAGR % | -8.94 | - | - | 8.49 | 9.9 | |||||
Inventory, 3 Yr. CAGR % | -11.65 | - | - | -6.71 | 21.59 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 26.32 | - | - | 21.62 | 11.22 | |||||
Total Assets, 3 Yr. CAGR % | 5.13 | - | - | -6.86 | -8.02 | |||||
Tangible Book Value, 3 Yr. CAGR % | -27.89 | - | - | 73.78 | -22.31 | |||||
Common Equity, 3 Yr. CAGR % | 6.12 | - | - | -3.85 | -10.19 | |||||
Cash From Operations, 3 Yr. CAGR % | -17.01 | - | - | 60.35 | -22.38 | |||||
Capital Expenditures, 3 Yr. CAGR % | 18.69 | - | - | 68.54 | 1.82 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -23.55 | - | - | - | -55.41 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -22.4 | - | - | - | -53.95 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | -2.45 | - | - | - | - | |||||
Gross Profit, 5 Yr. CAGR % | -4.7 | - | - | - | - | |||||
EBITDA, 5 Yr. CAGR % | -16.98 | - | - | - | - | |||||
EBITA, 5 Yr. CAGR % | -12.86 | - | - | - | - | |||||
EBIT, 5 Yr. CAGR % | 0.09 | - | - | - | - | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 20 | - | - | - | - | |||||
Net Income, 5 Yr. CAGR % | 19.99 | - | - | - | - | |||||
Normalized Net Income, 5 Yr. CAGR % | 0.93 | - | - | - | - | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 20.02 | - | - | - | - | |||||
Accounts Receivable, 5 Yr. CAGR % | -4.52 | - | - | - | - | |||||
Inventory, 5 Yr. CAGR % | 3 | - | - | - | - | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 8.92 | - | - | - | - | |||||
Total Assets, 5 Yr. CAGR % | 12.89 | - | - | - | - | |||||
Tangible Book Value, 5 Yr. CAGR % | -45.01 | - | - | - | - | |||||
Common Equity, 5 Yr. CAGR % | 6.76 | - | - | - | - | |||||
Cash From Operations, 5 Yr. CAGR % | -15.45 | - | - | - | - | |||||
Capital Expenditures, 5 Yr. CAGR % | -15.66 | - | - | - | - | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -1.12 | - | - | - | - | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 0.05 | - | - | - | - |
- Stock Market
- Equities
- MYGN Stock
- Financials Myriad Genetics, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















